As Indian medical visas granted to Pakistani patients regularly make headlines in India, it is hard not to conclude that it's all part of a PR campaign by the Hindu Nationalist Modi government in India.
Pakistan is an important and lucrative source of medical tourism dollars in India. The kind of facilities Pakistanis pay to use in India are not accessible to poor Indian masses who must rely on India's decrepit public health system.
A 2017 report by Indian ministry of commerce and industry says an average Pakistani spends Rs 187,000 on treatment in India. Those from Bangladesh spend Rs 134,000 on an average, followed by those from Commonwealth countries (Rs 125,000), Russia (Rs 104,000) and Iraq (Rs 98,554).
Times of India quoted Manish Chandra of Vaidam medical travel agency as saying: "This is because Pakistani patients mostly come for organ transplants and heart surgeries for children that are costly." In 2015-16, he said, nearly 166 Pakistanis received treatment in India every month. Top Delhi hospitals, which are frequented by foreign nationals, confirmed this.
Most of the Pakistani patients suffering from liver and heart ailments go to major for-profit hospitals in Delhi, Mumbai, Chennai and other cities, according to TOI. The number of Pakistani patients, however, has seen a sharp drop since February this year when the Indian government decided to stop granting medical visas to retaliate after Pakistan handed out a death sentence to Indian spy Kulbhushan Jadhav. In other words, humanitarian concerns take a back seat to Modi government's policies to assert India's dominance in the region.
The Times of India sums up the situation as follows: India's imposition of restrictions on the issue of medical visas to Pakistanis has not just affected hundreds of patients from across the border but also dealt a body blow to medical tourism in India.
Is India Safe for Medical Tourism?
Indians Carry Heavy Disease Burdens
India Leads the World in Open Defecation
WHO Says India Leads the World in TB Cases
Infectious Diseases Kill Millions in South Asia
Infectious Diseases Cause Low IQ
Malnutrition Challenge in India and Pakistan
Hunger: India's Growth Story
Google Baby Boom in India
WHO Report on Medical Tourism in India
Why India should issue more medical tourism visas to Pakistani nationals
The highest average earnings per patient through export of health services from India comes from Pakistan at $2,906, says survey
The highest average earnings per patient through export of health services from India comes from Pakistan at $2,906. Pakistan is followed by Bangladesh ($2,084), CIS (Commonwealth of Independent States) countries ($1,950), Russia ($1,618) and Iraq ($1,530), according to a first of its kind survey on export of health services by Directorate General of Commercial Intelligence and Statistics, under the commerce ministry. This means a patient from Pakistan visiting a hospital in India spends more than people from any other country, boosting India’s foreign exchange reserves.
However, the number of medical visas issued to Pakistani patients in 2015-16 stood at a measly 1,921 compared to 58,360 to patients from Bangladesh and 29,492 to patients from Afghanistan. Due to the low number of medical visas issued, Pakistan contributed only $6 million to India’s services exports compared to $343 million by Bangladesh in 2015-16.
India has emerged as a top-notch destination for medical value travel because of its world-class healthcare facilities and affordable price. India aims to significantly promote medical tourism and has recently liberalized its e-visa system for most of the countries except Pakistan.
In the health tourism portal maintained by the services export promotion council as a one-stop for overseas patients, there is no specific information on how patients from Pakistan can obtain a medical visa. The same information is available for patients from 16 countries, including Bangladesh and Afghanistan.
The tension between the two South Asian neighbours has risen after a Pakistan military court handed a death sentence to captured Indian national Kulbhushan Yadav who Pakistan alleges is an Indian spy. India has denied the charge and has repeatedly asked for consular access to Yadav that Pakistan has refused time and again. There are reports that India may further restrict visas to Pakistani nationals, though another report claims visas will be issued to Pakistan nationals only on medical ground.
Pakistani nationals can get visitor visa of six months to meet relatives or friends or any other legitimate purpose and the duration of stay in India at a time shall not exceed three months. “However, senior citizens (above 65 years of age) or a Pakistan national married to an Indian and their children below 12 years of age accompanying parents may be granted two years visit visa with multiple entries subject to certain conditions,” minister of state in the ministry of home affairs Kiren Rijiju said in response to a question in Rajya Sabha earlier this month.
When I was doing my residency we had a few genetic disorders from Pakistan and these are very difficult cases. There is high prevelance of consanguinity (intra-family) marriages in Pakistan.
SP: "There is high prevelance of consanguinity (intra-family) marriages in Pakistan"
It's true of larges parts of South Asia, including India.
Read the following report published in NY Times:
In South Asian Social Castes, a Living Lab for Genetic Disease
By STEPH YIN JULY 17, 2017
Along with David Reich, a geneticist at Harvard Medical School, Dr. Thangaraj led an effort to analyze data from more than 2,800 individuals belonging to more than 260 distinct South Asian groups organized around caste, geography, family ties, language, religion and other factors. Of these, 81 groups had losses of genetic variation more extreme than those found in Ashkenazi Jews and Finns, groups with high rates of recessive disease because of genetic isolation.
South Asians should be viewed not as a single population but as thousands of distinct groups reinforced by cultural practices that promote marrying within one’s community. Although recent changes to cultural norms have resulted in more marriages between members of different groups like castes or subcastes, especially in some urban areas, gene flow between populations was restricted for millenniums, the authors report.
Marriage within a limited group, or endogamy, has created millions of people who are susceptible to recessive diseases, which develop only when a child inherits a disease-carrying gene from both parents, said Kumarasamy Thangaraj, an author of the study and a senior scientist at the Center for Cellular and Molecular Biology in Hyderabad.
Today, South Asia consists of around 5,000 anthropologically well-defined groups. Over 15 years, the researchers collected DNA from people belonging to a broad swath of these groups, resulting in a rich set of genetic data that pushes beyond the field’s focus on individuals of European ancestry, Dr. Reich said.
The scientists then looked at something called the founder effect. When a population originates from a small group of founders that bred only with each other, certain genetic variants can become amplified, more so than in a larger starting population with more gene exchange.
The strongest of these founder groups most likely started with major genetic contributions from just 100 people or fewer. Today, 14 groups with these genetic profiles in South Asia have estimated census sizes of over one million. These include the Gujjar, from Jammu and Kashmir; the Baniyas, from Uttar Pradesh; and the Pattapu Kapu, from Andhra Pradesh. All of these groups have estimated founder effects about 10 times as strong as those of Finns and Ashkenazi Jews, which suggests the South Asian groups have “just as many, or more, recessive diseases,” said Dr. Reich, who is of Ashkenazi Jewish heritage himself.
Why do Pakistanis travel to India for medical treatment? Why don;t they build facilities at home?
Rahul: "Why do Pakistanis travel to India for medical treatment? Why don;t they build facilities at home?"
My answer to your questions is implicit in the following questions:
Why do so many Indians travel abroad for medical treatment? Why did Sonia Gandhi go overseas for treatment in March 2017?
Why do Indians import almost all of their surgical instruments from Pakistan? Why do Indians depend heavily on Chinese imports for almost everything? Why don't they do it all themselves?
Or for that matter, why do nations trade? Why does't each nation make everything and provide all services within the country? Surely, a nation as large as India with over a billion strong consumer market should be able to do that?
Why does US depend so heavily on Chinese imports? Even for critical parts of their advanced fighter jets and other defense equipment? Surely, a nation as advanced as US should do it all themselves.
India imports almost all surgical equipment from Pakistan..ROFL..got any proof?
"This is because Pakistani patients mostly come for organ transplants and heart surgeries for children that are costly."
Unlike other countries where even the more basic procedures and medical treatments are unavailable, Pakistanis only come for more complicated procedures that are not available in Pakistan. So fewer of them come and each spends more.
Anon: "India imports almost all surgical equipment from Pakistan..ROFL..got any proof?"
Here's a Times of India report on India's dependence on surgical equipment imports from Pakistan:
Call it a case of surgical strikes with a difference. It involves Pakistan and cross-border targets, but in this case India is continually at the receiving end, and happily so.
Suppliers in India eagerly await the next consignments of surgical instruments from across the border, where a pre-Partition industry set up in what is now Pakistan's Punjab province continues to produce more competitive surgical instruments.
The worsening of political ties between the two countries notwithstanding, India imports scissors, forceps and other surgical instruments such as needle holders and retractors from Pakistan, not only for domestic use but also for export to Afri can countries, among others.
Indian artisans sought to compete with their Pakistani counterparts but eventually gave up, suppliers told ET. "These instruments are manufactured with the aid of hammer forging, a technique available in Pakistan," said Vipin Yadav, owner of Leo Manufacturer Manufacturers.
"Setting up an industry having this technique will entail substantial cost, which we won't be able to bear without government support. While we manufacture 50 pieces a day, Pakistan, with the help of hammer forging, produces 5,000 pieces a day. And at a much cheaper price."
Sialkot is the global centre of surgical instrument manufacture – around 80 per cent of the world’s supplies are made here, and then shipped abroad.
The umbrella term “surgical instruments” summarises the specific and mostly hand-held instruments used during an operation or a surgery (e.g. scalpels, clamps and forceps). Worldwide these instruments are mainly produced in two traditional clusters – in Sialkot, Pakistan and in Tuttlingen, Germany. Together, these clusters supply up to 75 % of the world demand of traditional hand-held stainless steel surgical instruments . As Figure 1 illustrates, not all of the instruments made in Pakistan are directly sold to the end customer. Instead, many of the Pakistani instruments are first transported to Germany where they often get final finishing and quality control .
"Sialkot is the global centre of surgical instrument manufacture – around 80 per cent of the world’s supplies are made here, and then shipped abroad."
And yet it hardly earns any forex for Pak , so that Pak stops begging every year to take care of balance of payment.
Can you be proud of something really worth to be proud of ?
TD: "And based on this article in https://www.dawn.com/news/1279191 it seems Pakistan's share of surgical equipment is 2%. Also what is this"
AS is your habit of trolling and spamming, you claim in above comments posted on Viewpoint From Overseas Youtube channel that Pakistan has only 2% marketshare of surgical instruments.
Your poor education shows through your comments like this one. Pakistan makes 75-80% of the world's supply of surgical equipment but gets only 2% of the value because the branding companies take most of the value....it's true of most branded products from iPhone to Nike where the manufacturer gets a tiny portion of the value and the brand gets most of it.
Home » OpinionLast Published: Tue, Sep 05 2017. 12 42 AM IST
Is India really cheaper than the US?
The Penn Effect is that prices of goods and services in developed countries (DCs) are, after using market exchange rates, substantially higher than those in less-developed countries (LDCs). The World Bank in 2015 estimated that prices are more than three times higher in the US than in India. This price differential is huge. This raises some interesting questions.
Why aren’t very many tourists from the US attracted to India, if the prices are very low in India? Also, the price differential can be attractive to migrants who had initially shifted from India. In their retirement years, the migrants could return home but this hardly happens.
Prices in the US are, as mentioned earlier, more than three times the prices in India. Let us consider this number in perspective. Pension funds in the US are, as discussed by Richard A. Marin, still going through a near-crisis as they have large unfunded liabilities. The size is still debated. If the shortfall is a quarter of the liabilities, then on one hand, a shortfall of 25% is viewed as a near-crisis. On the other hand, there is an opportunity to get 200% more by shifting to India! But we do not see this behaviour.
there is often a risk in purchases. For example, medical charges can be relatively low in India but there is a question mark about the competence of a medical practitioner (and even about the arrangements in many hospitals). So, the risk-adjusted price can be higher than the observed price.
quality is low in India. This is well known but not adequately appreciated. For example, while the cost of higher education in India is low, the quality too is typically quite low. So, the quality-adjusted price of education can be high in India.
It is true that the use of market exchange rates can underestimate the gross domestic product of a country like India relative to that of a DC. So many economists advocate the use of exchange rate based on PPP. However, this can overestimate the GDP in India. So, it may help to consider adjusted-PPP to get the correct picture.
India's healthcare: Private vs public sector
In August, at least 386 children were reported to have died at a public hospital in the north Indian city of Gorakhpur in Uttar Pradesh. This sudden rise in fatalities at the Baba Raghav Das (BRD) Hospital placed India's healthcare system under scrutiny. Authorities attributed the increase to a seasonal encephalitis outbreak, but others have placed the blame on corruption within India's public healthcare system.
According to the United Nations, in India, about 48 out of every 1,000 newborns die before reaching the age of five. It is one of the highest under-five child mortality rates in South Asia (behind Afghanistan at 91 and Pakistan at 81). In terms of numbers, India has the largest share of global under-five deaths at 1.3 million annually.
About five percent of the Indian government's annual expenditure goes towards healthcare. According to the World Health Organization (WHO), most of the healthcare expenditure in India - which averages $75 per capita - comes from the private spending of households.
The standards of India's public healthcare system contrast starkly with its private counterpart, which generates billions of dollars annually from medical tourism.
For local Indians, the cost of private healthcare is about four times greater than the country's public healthcare. About 72 percent of residents of rural areas and 79 percent of residents of urban areas use private healthcare services.
Did this article:
cause this deportation?:
India plans to lessen its drug reliance on China
Currently, India gets 70-80% of its medicines and medical devices supplies, including raw material for pharmaceuticals (Active Pharmaceutical Ingredient) from China. This poses a major risk of severe drug shortage if India's diplomatic relations with China worsen.
In fact, in 2014, National Security Adviser Ajit Doval had also warned the government about India's over-dependence on China for API and how the tension between the two countries can cause a crisis in the public health ..
Swiss tourist couple badly injured in youth assault at #Agra #India. #Tourism #TajMahal
Youths would later tell the police that the couple, both 24, had offended them by ignoring their greetings and kissing in front of them. Not so, Ms. Droz told The Times of India. They were trying to force her to take selfies with them, Mr. Clerc added. Eventually, they began beating the couple with sticks and rocks.
By the time a crowd had gathered and the youths had run away, he had a fractured skull and possibly permanent hearing damage and she had a fractured left arm. “The blood was flowing,” said Ram Kishor, a police constable in the area.
The assault late last month made headlines for several days in India. It was a fresh setback for tourism in this part of the country, which is home to some of the world’s most famous monuments but finds its status threatened by disputes about its Muslim heritage, amid reports of declining visitor numbers and of harassment of tourists.
Stops at Fatehpur Sikri and in the nearby city of Agra to see the Taj Mahal, all of which are in Uttar Pradesh State, are at the top of many itineraries for tourists in India. Built in the 17th century by the Muslim emperor Shah Jahan as a tomb for his wife, Mumtaz Mahal, the Taj Mahal attracts millions of visitors every year. Tour operators call it India’s monument to eternal love.
But Hindu nationalists, some of them aligned with the governing Bharatiya Janata Party, have taken aim at the Taj Mahal and its ties to a Muslim ruler.
During a trip to Agra in June, Yogi Adityanath, the chief minister of Uttar Pradesh, said at a rally that small replicas of the monument given to foreign dignitaries “did not reflect Indian culture.” Other far-right leaders went further, describing it as having been built by “traitors” who “wanted to wipe out Hindus.”
But Mr. Adityanath seems to be softening his stance, at least in public. When he visited Agra in late October, he called the Taj Mahal a “unique gem.” A tourism brochure published by the state government that initially omitted the Taj Mahal has been updated to include it.
Tour guides said the controversy had hurt their business.
On a recent day, a throng of tourists formed a line at the mouth of the Taj Mahal complex, pressing their bodies forward. Among them was Vital Labonte, 66, a French Canadian visitor in hiking boots, who said the occasional jostle or appeal for money did not bother him.
“The kids run at you, they want money to better their life,” he said. “Just say no. I’m not worried with it.”
Viktoria Simeoni, 23, an Austrian visitor who had booked a trip to India on a whim, said she sometimes felt unsafe when men stared at her or asked for pictures, a request often made to foreign tourists in India.
“One lady gave me her baby,” she said. “I was just holding the baby, and then she took pictures of me. I didn’t feel so comfortable.”
The police found it necessary to crack down. In the days after the attack, they arrested over 50 people they accused of being touts with reputations for hounding tourists.
In Fatehpur Sikri, officials emphasized that the severity of the attack against the Swiss couple was rare. The crime that tourists report most often is theft.
BBC News - Anger as #India doctor mistakenly declares newborn dead. #Health #MedicalTourism
A newborn baby, declared dead by a hospital in the Indian capital Delhi, was found to be alive while they were on their way to his funeral.
Doctors at the privately run Max Hospital had pronounced the baby dead hours after his twin who was stillborn.
The parents said they noticed one of the babies squirming inside the plastic bag that doctors placed the infants in.
The incident has sparked outrage and a debate over the quality of private healthcare which is often costly.
Delhi Chief Minister Arvind Kejriwal tweeted that he had ordered an inquiry into the matter. The state health minister has also described the incident as "shocking criminal negligence".
According to the twins' grandfather, the stunned family rushed the newborn to a nearby hospital where they were told that their baby was still alive, local media reported.
In a statement to reporters, Max hospital said they were "shaken" and "concerned" over the incident, and added that the doctor has been asked to go on leave, pending an inquiry.
According to ANI news agency, Delhi police have begun to investigate the case and have consulted legal experts.
This is the second instance in recent months where a private hospital in India has been called out for negligent care. Last month, a girl died of dengue fever in another hospital and the parents allege they were overcharged for her treatment.
Uttar Pradesh #India: #Cataract surgery on 32 patients under flash light; Doctor suspended. #MedicalTourism http://indianexpress.com/article/india/up-cataract-surgery-done-under-torchlight-sidharth-nath-singh-removes-cmo-unnao-4999430/ … via @IndianExpress
Uttar Pradesh Health Minister Sidharth Nath Singh on Tuesday removed Chief Medical Officer of Unnao Rajendra Prasad after it was reported that doctors at Community Health Center of Nawabganj conducted eye operations of 32 patients under torchlight on Monday night.
“Taking a serious note of the matter, the Uttar Pradesh government acted promptly and suspended CMO Rajendra Prasad,” Singh said. He said incharge of the community health centre (CHC) at Nawabganj has also been removed. A report has been sought by the state health department regarding the entire episode.
Earlier, the Chief Medical Officer said the acting district magistrate has ordered an inquiry into the matter and the organisation entrusted with the task could be blacklisted if found guilty.
Meanwhile, some relatives of the patients complained that they were not provided with any beds after the procedure, and that they were made to lie down on floors despite extreme cold weather conditions.
Uttar Pradesh has attracted bad press for a series of ‘medical disasters’ in the recent past, with the death of more than 60 children, mostly infants, at a government hospital in Gorakhpur being the latest case in point. A hospital in Farukhabad recorded 49 deaths — 30 in neo-natal ICU and 19 during delivery — between July 20 and August 21 this year, reportedly due to a lack of oxygen supply.
‘Pakistan ahead of developed countries in neurosurgery’
LAHORE: At a three-day international conference on neurosurgery, Prof Dr Khalid Mahmud in the presence of international delegates, professors of Punjab Institute of Neurosciences and Lahore General Hospital Unit 2 gave live training of endoscopy operations.
All the participants were delighted with the professional capabilities and expertise of Dr Khalid, who also presented his research papers and enlightened the audience with some of his career’s most complicated cases.
He said that Pakistani doctors in the past had to go abroad for training, but now the experienced doctors from Pakistan were sharing their experiences with those in other countries. Dr Khalid said that Pakistan was ahead of the developed countries in neurosurgery, especially in endoscopy. He called upon the young doctors to opt for modern techniques and provide the best possible medical facilities to the patients.
It is pertinent to mention here that apart from Pakistani doctors, the Neuro Surgeons Conference was attended by those from the US, KSA, Korea, Nepal, Russia, Italy, and the Czech Republic, who also shared their experiences. Surgical anatomy, brain path and sinonasal also came under discussion during the Skype sessions that were held to demonstrate endoscopy tumour biopsy and a live surgery was also undertaken.
Dr Khalid claimed that brain tumours were being removed in the Punjab Institute of Neurosciences of the Lahore General Hospital without opening the head, and that too free of cost for the poor. He told that the loss of blood in the process was minimal and the patient has to minimum time at the hospital.
He said that state-of-the-art facilities were available in the Punjab Institute of Neurosciences where complicated operations were being undertaken in large numbers.
August 16, 2018, 2:00 AM IST Rohit Saran in TOI Edit Page | Edit Page, India, World | TOI
It may have looked moth-eaten to its founder Mohammad Ali Jinnah, but Pakistan was anything but that at the time of Independence. An average Pakistani was richer, lived longer and lived more safely than an average Indian for almost two decades after 1947, which is roughly the time democracy was absent in Pakistan.
What can India offer to Prime Minister Khan that’s new, substantive and outside the immediate no-go areas of J&K and terror? We should first banish the thought that a weak Pakistan is good for us. A crippled Pakistan is only good for two things: 1. Shouting matches on TV where those criticising India are asked to migrate to Pakistan. 2. To give us a false sense of achievement in doing better than Pakistan when India’s potential-performance gap is much wider than Pakistan’s.
A less hostile public attitude toward our neighbour will allow government to take a few out-of-the box steps. For instance, Indian companies should be allowed and encouraged to hire from top Pakistan campuses, even if for one or two years. If only 30 Sensex companies hire 50 Pakistanis each, there will be 1,500 young and talented Pakistanis working and living in India benefiting, and benefiting from, the world’s 6th – and soon to be 5th – largest economy. Companies will get good talent at competitive salaries – Pakistani rupee is nearly half the value of Indian rupee. For those worrying about a job loss for Indians, 1,500 is only 0.0007% of Sensex companies’ workforce.
Imran Khan’s passport has more Indian visas than any prime minister of Pakistan. Unfortunately, India allows only the rich and powerful in Pakistan to benefit from India’s soft power. That’s counterproductive to our own interests. We should want average Pakistanis to see India as a source of good to them. They will then begin to resent whatever power comes between that ‘good’ and them – whether that power is in Rawalpindi or Islamabad or Beijing – or even Srinagar.
Aspiring cricketers in Pakistan will dream of playing in IPL if we unblocked their entry. A budding artist (actors, singers, comedians …) in that country will look forward to hitting the big stage in India, if we don’t hum and haw over granting him a visa. Pakistanis with a critical medical condition in the family should want to get treatment in India – without having to try their luck on Sushma Swaraj’s Twitter handle. Pakistan should be allowed to fill its quota of students at the South Asian University, something we committed to at the time of deciding to host this institution that could one day be the region’s most coveted.
Not one of these will be acts of charity or concession because India’s gains will be as much as Pakistan’s – if not more. This is exactly what we tell the US while arguing for easier immigration. In geopolitics there is no positive emotion as powerful as seeing your countrymen excel in another country. India has that power in its grasp today. Let’s use Imran’s prime ministership as an occasion to unleash that power.
#UAE to build first ever #medical mall in #Islamabad, #Pakistan. The project will include therapeutic and recreational areas, a regional #Cardiology center, an orthopedic centre and 400-bed #university #hospital. https://www.thenews.com.pk/latest/357797-uae-to-build-first-ever-medical-mall-in-pakistan
A prominent UAE-based MBF Group has announced to establish an integrated medical city that will also feature a first-ever medical mall of the country in Islamabad.
The agreement of MBF with Ibchez Housing and Nixon, according to the report, will include the construction of a hospital that will provide medical services at international standards.
The founder and owner of MBF Group Shaikh Mohammad Bin Faisal Al Qasimi ,in an interview with the Gulf news said the project will include a 400-bed university hospital that will offer the most advanced levels of healthcare services.
The medical city will also feature the country’s first medical mall, therapeutic and recreational areas, a regional cardiology centre, and an orthopedic centre, he added.
He noted that the city will include a nursing college and is expected to serve some one million patients and clients on a monthly basis.
There is a need for such advanced hospitals to serve Pakistan’s growing population, he stressed.
Shaikh Mohammad pointed out that the investment provided for the medical city has reached US$970 million (Dh3.52 billion), while noting that its land has been purchased, as well as the desire of all parties to complete the project on time, in a bid to answer the growing demand for medical services in Islamabad and provide specialist health services that are in short supply.
He informed that the group will manage the city’s 1,000 medical, technical and administrative staff, who will all be Pakistanis, and is responsible for providing medical equipment and beds.
Not all is well with #India's corporate #hospital chains. The sharpest dip is witnessed in the National Capital Region (NCR), where operating margins have declined by 21 percentage points. #medical #health #tourism https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/not-all-is-well-with-indias-corporate-hospital-chains/articleshow/65545784.cms
Four of India’s large publicly traded hospital chains — ApolloNSE 4.37 %, Narayan Health, Fortis and Max IndiaNSE -1.34 % — have cumulatively lost `6,300 crore in market cap in the last two years, an analysis by ET Intelligence Group showed. A report by rating agency ICRA in July revealed that profitability of hospitals have touched a multi-year low.
“The health of the hospital sector has been deteriorating since early CY2017 due to several factors that have adversely affected its profi ..
#Indian woman undergoes successful weight loss #surgery in #Pakistan. Sources told media that Maali Saasan had come to Pakistan after a failed attempt in #Mumbai, #India.
ISLAMABAD: A Pakistani doctor has done a successful weight loss Bariatric surgery on 37-year old Maali Saasan, an Indian citizen in Pakistan.
Sources told media that Maali Saasan had come to Pakistan after a failed attempt in Mumbai, India.
She said that she had lost only 15 kg in her first surgery whereas Dr Maaz has removed more fat from her body as she had 150 kg weight which came down to 80kg.
Dr Maaz has set a remarkable example which is a good initiative to strengthen the image of Pakistan across the world, doctors said.
#India gets around 68% of its raw materials -- known as active #pharmaceutical ingredients (APIs) -- from #China. Any disruption in that supply chain can create a major problem, especially during a #pandemic. #coronavirus #COVID #UnitedStates #SupplyChain https://www.cnn.com/2020/05/16/business-india/india-pharma-us-china-supply-china-intl-hnk/index.html
In the US, 90% of all prescriptions are filled by generic drugs and, one in every three pills consumed is produced by an Indian generics manufacturer, according to an April 2020 study by the Confederation of Indian Industry (CII) and KPMG.
While the US seems to hold sway with its ally India in obtaining the finished product, there's a bigger issue earlier in the supply chain.
India gets around 68% of its raw materials -- known as active pharmaceutical ingredients (APIs) -- from China. Any disruption in that supply chain can create a major problem, especially during a pandemic.
As scientists and pharmaceutical companies race to find an effective treatment and vaccine for Covid-19, there are fears the current vulnerabilities in the supply chain could expose the US -- and other countries -- to drug shortages, just when they need them most.
The US has pledged to "Buy American" drugs going forward, and Indian plans to ramp up its own API production, but will they be able to replace supplies from China during this pandemic -- or even the next?
India's rise in global pharma
India's rise as a global producer of cheap pharmaceuticals began when the Indira Gandhi administration passed the Patent Act of 1970, which granted legal protection only to the processes used to make a drug, not a drug's content.
Karan Singh, managing director of Indian pharmaceutical company ACG Worldwide, says the government realized its huge population was never going to be able to afford imported patented drugs, and needed to find a solution.
Indian companies excelled in reverse engineering big-name drugs and launched copycat versions -- legally. But it wasn't only India that wanted these products, and in the mid-1980s, regulatory changes opened up the US market more open to cheap copycat drugs, too.
Naturally, the pharmaceutical giants, which had invested millions of dollars in creating new drugs, pushed back, and in 1995 the World Trade Organization (WTO) introduced an agreement giving drug patents 20 years' protection -- and companies were given 10 years to comply.
But when the HIV/AIDs crisis hit durig that 10-year transition window, it was clear that poor countries needed cheap drugs -- in 1999, the most common cause of death in sub-Saharan Africa, where many people couldn't afford antiretrovirals, was HIV/AIDs.
The WTO conceded that member states could grant licenses to manufacturers to make generic versions of patented medicines needed to protect public health.
In 2001, an Indian pharmaceutical company, Chemical, Industrial and Pharmaceutical Laboratories (Cipla), reverse-engineered several brand-name drugs, and combined them in a revolutionary anti-HIV drug cocktail. African countries and aid groups were offered the drug for $1 a day, a discount of more than 96% on brand-name versions.
Now that company is working to reverse engineer three drugs being tested to fight Covid-19 -- Remdesivir, Favipiravir and Baloxavir. "Twenty years later we are again in the forefront here in India with regards to medicines necessary to combat Covid-19," said Dr Yusuf Hamied, chairman of Cipla.
Still, overcoming challenges from intellectual property rights is only half the story.
Few current antibiotics can combat bacteria that have the NDM-1 gene, making it potentially dangerous.
NDM-1 stands for New Delhi metallo-ß-lactamase-1. A medical team first isolated the gene in a Swedish patient of Indian origin who traveled to India in 2008.
What led to the emergence of NDM-1 in India is not clear.
This superbug is widespread in India, and, by 2015, researchers and medical experts detected it in more than 70 countries worldwide.
In this article, we explore the nature and possible dangers of bacteria with the NDM-1 gene.
The World Health Organization (WHO) is concerned that NDM-1 could see in “the doomsday scenario of a world without antibiotics.”
Before the discovery of antibiotics in 1928, many people died because of infections that are now avoidable.
NDM-1 raises fears that diseases in the future will not respond to antibiotics. If NDM-1 crosses over into other bacteria, secondary diseases will emerge, causing a health crisis as they spread around the world.
The WHO suggest that a woman who is pregnant, for example, could develop a kidney infection that transfers into the bloodstream with a strain containing NDM-1. In this case, no treatment options would be available that are safe for a woman during pregnancy.
The NDM-1 gene causes bacteria to produce an enzyme called a carbapenemase. Carbapenemase renders many preferred types of antibiotic ineffective, including carbapenems.
Carbapenem antibiotics are extremely powerful drugs that can counter the activity of highly resistant bacteria for which other antibiotics have not been effective. Even
carbepenems are ineffective in cases of NDM-1.
A bacterium with a plasmid containing the NDM-1 protein product has the potential to be resistant to many current antibiotics, as well as newer antibiotics that could become available in the near future.
Research is on-going into possible solutions to NDM-1.
New Delhi killer superbug hits Tuscan tourist paradise
Authorities in Tuscany, home to some of Italy's most visited tourist attractions, have stepped up hospital controls after a deadly outbreak of the New Delhi superbug.
The antibiotic-resistant killer has shown "significant diffusion in the northwestern area of Tuscany" since November 2018, infecting at least 75 people, local health authority ARS said.
The bacterial disease is believed to have killed at least 31 people in 17 different hospitals since then, Italian media reported Thursday.
More than 31 cases were reported in Pisa, home to the famous leaning tower.
Superbug NDM-1 (New Delhi metallo-beta-lactamase 1) sparked a global panic when it was found in the Indian capital in 2010 and showed resistance even to carbapenems, a group of antibiotics often reserved as a last line of defence.
The European Centre for Disease Prevention and Control in June issued a rapid risk assessment after a "large outbreak" of the New Delhi superbug in Tuscany.
It warned of possible cross-border infections, "especially since the affected area is a major tourist destination."
Tuscany's health authority said "the ability to resist antibiotics makes these bacteria dangerous, especially in vulnerable patients, already affected by serious pathologies or immunosuppressed."
As a result, hospitals in the region have "stepped up procedures for the prevention and control of infections in health facilities," it said.
What is superbug NDM-1’s India connection?
After a 70-year-old American woman died of the superbug NDM-1 (New Delhi Metallo-beta-lactamase-1) in November last year, health officials recently revealed that her infection was resistant to all the available antibiotics, raising major concerns in the health community.
Here’s all you need to know about the superbug, the infection it causes, where it’s found and its effects:
NDM-1 (New Delhi Metallo-beta-lactamase-1) is an enzyme that makes bacteria resistant to a wide range of powerful antibiotics, including the carbapenem class of antibiotics that are used to treat multidrug-resistant infections.
The gene for NDM-1 encodes beta-lactamase enzymes called carbapenemases, which makes bacteria resistant to antibiotics, including carbapenem, which is used to treat other superbugs such as methicillin-resistant Staphyloccus aureus (MRSA).
Bacteria that produce carbapenemases are popularly referred to as superbugs because they are difficult to treat and result in the infection spreading easily within the body, especially in people who are ill or recuperating from an illness or a surgery.
People die of septic shock after the infection enters the bloodstream and reached the heart, lungs, kidneys, bones or joints to cause multi-organ failure.
The enzyme that makes bacteria drug resistant got New Delhi in its name because it was first detected in 2008 in Swedish patient of Indian origin who had travelled to India.
NDM-1 has been detected in bacteria in the UK, US, India, Pakistan, Croatia, Canada and Japan.
The first death was recorded in Belgium, where a man who was treated in a hospital in Pakistan died in August 2010.
The most common bacteria that make this enzyme are E. Coli and K. pneumoniae, but the NDM-1 gene can spread to other bacterial strains.
NDM-1 in India: Drug Resistance, Political Resistance
It's been more than a year since the "Indian superbug" NDM-1 – not actually a bacterium, but a gene that directs production of an enzyme – hit the news. The enzyme, whose acronym is short for New Delhi metallo-beta-lactamase-1, disables almost all antibiotics directed against it, leaving the bacteria in which the gene appears vulnerable to only two imperfect and sometimes toxic drugs.
The enzyme and its gene, blaNDM-1, were first identified in 2008 in people who had traveled in India or sought medical care in South Asia. Hence its name: Many beta-lactamases, enzymes that denature the very large class of everyday antibiotics known as beta-lactams, are named for countries and cities where they were first identified. Since its identification, NDM-1 has been discovered in patients in more than a dozen countries and has also been found to be widely harboured outside hospitals in India, and in surface waters and sewage there.
The unveiling of NDM-1 clearly caused embarrassment for India, and media and lawmakers there struck back, throwing around intemperate language and claiming the naming of the enzyme was a plot to derail the subcontinent's medical-tourism industry — even though the Indian doctors hadattempted to raise the alarm earlierand had been ignored.
So it seemed like a promising signal of openness when an international conference on antibiotic resistance opened in New Delhi a week ago. But in its wake, just what is going on in India – and whether its government is willing to face up to what might be an international crisis – is less clear than ever.
If India is moving to contain NDM-1, it is doing so barely in time. Dr. Timothy Walsh, who first isolated the gene and enzyme in a resident of Sweden who had been hospitalized in India, told the Times of India:
We estimate that the carriage rate of NDM-1 in India is between 100 and 200 million, which means that NDM-1 has become a very serious public health issue... With globalization, NDM-1 will continue to spread unchecked around the world and once established in higher enough numbers in a particular country, will further disseminate.
We are desperate to help in any way we can to initiate studies to realize the full impact of NDM-1 on Indian society... I cannot say whether the Indian government is finally taking the issue seriously – only they can answer that charge. However, what is clear is that we have lost a year fighting amongst ourselves when our energies and resources should have been focused elsewhere – on NDM-1.
The growing peril of drug-resistant superbugs
Many in India face a similar fate – they get admitted to hospitals with seemingly treatable illnesses, only to contract HAIs caused by superbugs.
Manoj Ghamandayan, 21, has little memory of the month he was hospitalised and nearly died.
It started out as a fever in the first week of October 2019. Then he began to have trouble breathing. Soon, Ghamandayan, an undergraduate Arts student from Haryana’s Jhajjar district, was admitted to Sunflag Global Hospital in Rohtak. He was diagnosed with dengue, a viral infection spread by the Aedes mosquito and scrub typhus, a bacterial infection. To help him recover, the hospital hooked him to multiple devices: a mechanical ventilator to aid breathing, a catheter for draining urine, and a central line to pump medicines into his body.
But Ghamandayan got sicker. During his two-week stay at the hospital, he caught three healthcare-associated infections (HAIs) or infections that patients catch at hospital. Invasive devices like ventilators, central lines and catheters pose the risk of HAIs because they breach the body’s protective barriers.
For example, a ventilator’s breathing tube could easily transfer bacteria from a nurse’s hands to the patient’s lungs, triggering pneumonia.
Ghamandayan came down with two bacterial infections, Escherichia coli and Acinetobacter baumanii, and a fungal species called Candida.
These pathogens were superbugs — i.e, resistant to multiple antimicrobial drugs — which make them hard to treat. His family moved him to New Delhi’s Sir Gangaram Hospital, where his doctor, Atul Gogia, deployed two last-line antibiotics called colistin and meropenem —both expensive, with toxic side effects. Yet these drugs are the only hope for patients when all else fails.
Ghamandayan eventually got better and was discharged nearly a month after he was first hospitalised. In all, he had spent Rs 6 lakh on his treatment.
Many in India face a similar fate – they get admitted to hospitals with seemingly treatable illnesses, only to contract HAIs caused by superbugs.
Few Indian hospitals track their HAI rates, which is why it is hard to get a countrywide picture of this problem.
But several stand-alone studies show that India has higher rates compared to richer countries like the US. For example, a study by the International Nosocomial Infection Control Consortium, which surveyed data from 40 hospitals in 20 cities in India, between 2004 and 2013, found that for every 1,000 days that patients were hooked to ventilators in Indian cardiac Intensive Care Units, there were around 11 times as many pneumonia cases as in American hospitals. “The rates of infections in Indian hospitals are just unacceptably high,” says Ramanan Laxminarayan, a public-health expert at Washington DC’s Center for Disease Dynamics, Economics & Policy (CDDEP).
But that’s just part of the problem. Many of the bugs that cause these infections have learnt to tolerate powerful antimicrobial drugs. Unpublished 2019 data from a 20-hospital surveillance network run by the Indian Council for Medical Research (ICMR) shows that key hospital bugs, like Acinetobacter baumanii and Klebsiella pneumoniae, have grown widely drug-resistant.
Patients infected with any of these bugs often have to be treated with last line drugs, which are both expensive and toxic. Many of them succumb: A 2018 study, carried out in 10 Fortis Group hospitals found that patients with multidrug resistant infections were almost thrice as likely to die as those with susceptible ones.
As outbreaks of the coronavirus spread throughout the world, people are reminded over and again to limit physical contact, wash hands and avoid touching their face. The recent Netflix docuseries “Pandemic: How to Prevent an Outbreak” illustrates how the Islamic ritual washing, known as “wudu,” may help spread a good hygiene message.
The series focuses on Syra Madad, a Muslim public health specialist in a New York hospital, who takes a break to say her prayers at the Islamic Center of New York University. Before entering the prayer room, Madad stops to perform wudu, and washes her mouth and face as well as her feet.
Islamic law requires Muslims to ritually purify their body before praying. As a scholar of Islamic studies who researches ritual practices among Muslims, I have found that these practices contain both spiritual and physical benefits.
The Prophet Muhammad left detailed guidance for Muslims on how to live their lives, including how to pray, fast and stay ritually pure. This guidance is available in collections called the Hadith.
According to Islamic law, there are minor and major impurities. Minor impurities involve urinating, defecating and sleeping, among other practices. A person of Muslim faith is supposed to perform a ritual washing of their bodies before praying to get rid of these minor impurities.
Wudu is to be performed, as was done by the Prophet Muhammad, in a specific order before praying, which takes place five times a day. Before each prayer, Muslims are expected to wash themselves in a certain order – first hands, then mouth, nose, face, hair and ears, and finally their ankles and feet.
Muslim institutions have begun to recommend that people make sure to wash their hands for 20 seconds with soap before doing wudu. Emphasizing that wudu alone cannot prevent the virus from spreading, other Islamic institutions recommend that mosques supply extra soap and hand sanitizer near the washing area.
They have issued rulings to cancel Friday prayers, urged Muslims to wash their hands with soap regularly, refrain from touching their face and practice social distancing.
While people have cleared local store shelves of hand sanitizers, wipes, cleaning supplies, gloves and masks, basic hygiene practices remain the best way to prevent the spread of the coronavirus and other viruses.
At this time, Islamic practices that emphasize purity of body could help reiterate the importance of hygienic practices along with the use of soap or hand sanitizer, to reduce one’s vulnerability to the virus.
Ten newborn babies have died in a fire at a #hospital in #India's #Maharashtra state. The fire was caused by a short circuit in the SNCU (Sick Newborn Care Unit). #MedicalTourism #Health #Modi https://www.cnn.com/2021/01/09/india/india-hospital-fire-babies-intl-hnk/
Ten newborn babies died in a hospital fire in the western Indian state of Maharashtra on Friday, according to the country's state-run broadcaster Doordarshan.
The fire broke out in a local hospital's Sick Newborn Care Unit (SNCU) in Maharashtra's Bhandara district, Doordarshan said in a tweet on its verified Twitter account. Firefighters rescued seven other babies from the unit.
The fire was caused by a short circuit in the SNCU, said CNN affiliate CNN-News18, citing Maharashtra Health Minister Rajesh Tope.
"The investigations are going on," Tope said, adding that $6,813 (5 lakh Indian rupees) would be paid in compensation to each of the families affected. The state will also bear funeral and counseling costs.
"Whosoever is guilty in this will not be spared at all," Tope said. "It should be ensured that such type of incidences do not occur henceforth."
Indian Prime Minister Narendra Modi mourned the incident on Saturday morning. "Heart-wrenching tragedy in Bhandara, Maharashtra, where we have lost precious young lives. My thoughts are with all the bereaved families. I hope the injured recover as early as possible," he wrote on Twitter
The office of Indian President Ram Nath Kovind also tweeted in Hindi, "I am deeply saddened by the untimely death of infants in a fire accident in Bhandara, Maharashtra. My heartfelt condolences to the families who lost their children in this heartbreaking event."
Home Minister Amit Shah said in a tweet that he was "pained beyond words" by the "irreparable loss."
The country's Health and Family Welfare Minister, Harsh Vardhan, said he was in touch with Tope about the incident.
#Fake #vaccines administered in #India. #Medical scams are nothing new in India, where, during the country’s mammoth outbreak this spring, profiteers targeted vulnerable #COVID19 patients with fake drugs and oxygen. #Modi #BJP #fraud #pandemic https://www.nytimes.com/2021/07/04/world/asia/india-covid-vaccine-scam.html
As India intensifies its vaccination effort amid fears of another wave of the coronavirus, officials are investigating allegations that perhaps thousands of people were injected with fake vaccines in the financial capital, Mumbai.
The police have arrested 14 people on suspicion of involvement in a scheme that administered injections of salt water instead of vaccine doses at nearly a dozen private vaccination sites in Mumbai over the past two months. The organizers, including medical professionals, allegedly charged between $10 and $17 per dose, according to the authorities, who said they had confiscated more than $20,000 from the suspects.
“Those arrested are charged under criminal conspiracy, cheating and forgery,” said Vishal Thakur, a police officer in Mumbai.
More than 2,600 people came to the camps to receive shots of the Oxford-AstraZeneca vaccine, manufactured and marketed in India as Covishield. Some said that they became suspicious when their shots did not show up in the Indian government’s online portal tracking vaccinations, and when the hospitals that the organizers had claimed to be affiliated with did not match the names on the vaccination certificates they received.
“There are doubts about whether we were actually given Covishield or was it just glucose or expired/waste vaccines,” Neha Alshi, who said she was a victim of the scam, wrote on Twitter.
Siddharth Chandrashekhar, a lawyer who has filed a public interest lawsuit in Mumbai’s high court, described the scenario as “heartbreaking.” The court said it was “really shocking that incidents of fake vaccination are on the rise.”
Medical scams are nothing new in India, where, during the country’s mammoth outbreak this spring, profiteers targeted vulnerable Covid patients with fake drugs and oxygen. The police in West Bengal state are also investigating whether hundreds of people, including a local lawmaker, received fake vaccines there.
India has administered more than 340 million vaccine doses, but less than 5 percent of the population is fully vaccinated, according to the Our World in Data project at the University of Oxford. The country is reporting nearly 50,000 new cases daily and nearly 1,000 Covid deaths, numbers that are far lower than two months ago, although experts have always believed India’s official tallies to be vastly undercounted.
On Saturday, the pharmaceutical company Bharat Biotech reported that its Covaxin shot — the other vaccine in wide use in India — was 77.8 percent effective in preventing symptomatic illness, according to the results of a late-stage trial. Those results were published online but have not been peer-reviewed.
Fire in #Covid intensive care ward (#ICU) kills 11 people in Ahmednagar, #Maharashtra, #India. Most of the 11 patients who died suffocated from smoke. The survivors’ medical condition was not immediately known. https://www.nytimes.com/live/2021/11/06/world/covid-booster-vaccine
NEW DELHI — Eleven people died after a fire broke out in a coronavirus intensive care unit in the western state of Maharashtra, the latest in a series of fatal disasters in Covid-19 wards in India.
Hospital staff tried to douse the fire that started Saturday morning with fire extinguishers, but the flames spread quickly in the airtight room, cutting the power out and forcing people to flee to safety, said Shankar Misal, the fire chief in the Ahmednagar district.
“It created huge, black smoke inside. It was completely dark,” he said.
Within minutes, firefighters had shattered windowpanes and lifted out 15 patients from the 17-bed facility. Most of the 11 patients who died suffocated from smoke, Mr. Misal said. The survivors’ medical condition was not immediately known.
The fire department is investigating whether an electrical short circuit caused the blaze. The Covid-19 ward was among many built hastily across India to accommodate a deluge of patients through the pandemic.
India’s infection curve is down sharply from the peak of its second wave in June, but the country is still reporting about 13,000 new cases daily.
Maharashtra’s top elected official, the chief minister Uddhav Thackeray, wrote on Twitter to express his “deep anguish over the incident.”
India’s health system — fragile and underfunded even in normal times — has experienced enormous strain during waves of the pandemic. In June, hospitals in the capital, New Delhi, and the state capital of Maharashtra, Mumbai, ran out of beds, medical oxygen and staff, and turned away patients who died outside the gates.
The government of Prime Minister Narendra Modi has ramped up the country’s health care infrastructure, but health is managed at a state level in India, and the standard of care and conditions at hospitals vary greatly from one region to the next.
Patients are flocking to #India for surgery but "Indian #medical #tourism lacks effective regulations to govern the sector, which leaves it unorganized and lacking in monitoring". The quality of the services provided by these agents is not regulated. https://www.bbc.com/news/business-60569647
"India has the largest pool of clinicians in South Asia," explains Dinesh Madhavan, President of Group Oncology at International Apollo Hospital Enterprises.
"We are uniquely positioned thanks to our hospitality and rich culture, combined with modern as well as traditional medicine and therapy," he says.
And it's not just treatment for medical conditions like cancer. There has also been a sharp rise in patients arriving in India for cosmetic surgery procedures such as liposuction (removal of body fat) or hair grafts for baldness.
"We get patients from the US, Africa and Gulf regions," says Dr Satish Bhatia, a dermatologist and cutaneous surgeon in Mumbai. Dr Bhatia says he sees many flight attendants, looking for quick, non-invasive cosmetic procedures such as dermal fillers or Botox.
Dr Bhatia says that, on average, the price of most cosmetic procedures in the US, Europe and the Middle East are at least 50% higher than if done in India.
Like much travel, medical tourism ground to a halt during the pandemic, but Dr Bhatia says business is picking up again and he is confident it will continue to grow.
However, this boom in overseas patients has its downsides.
"There is a mushrooming of new aesthetic clinics all around India. Sadly, this also attracts unqualified and untrained doctors wanting to make easy money," says Dr Bhatia.
Always research your doctor's credentials and experience before fixing an appointment, he advises.
Patients should also make sure there are adequate arrangements in place for aftercare, says Dr Shankar Vangipuram, senior consultant, radiation oncology at the Apollo Cancer Centre in Chennai.
"Post-treatment in India - sometimes due to lack of qualified clinicians and diagnostic tools - we do face difficulty in tracking the responses and toxicities," he says.
The government meanwhile, acknowledges that the sector needs tighter regulation.
#India’s drug regulator has ignored red alerts on #COVAXIN, imperiling millions of lives. World #Health Organization warned #UN agencies against procuring Covaxin, India’s indigenously developed & manufactured #COVID19 #vaccine. #Modi #Hindutva #Bharat https://www.statnews.com/2022/04/15/indias-drug-regulator-has-ignored-red-alerts-on-covaxin-imperiling-millions-of-lives/
Why are CDSCO and others treating Bharat Biotech with kid gloves?
The simple answer is that virtually all of India has thrown its weight behind Bharat Biotech because of Prime Minister Narendra Modi’s AatmaNirbhar policy, which broadly translates into a policy of economic self-reliance. This has meant special regulatory privileges for Covaxin, given its status as a made-in-India vaccine that was developed with the support of the Indian Council of Medical Research (ICMR).
In a shocking turn of events, the World Health Organization warned United Nations agencies against procuring Covaxin, India’s indigenously developed and manufactured Covid-19 vaccine, just five months after granting approval to the made-in-India vaccine. The warning came after a WHO inspection of a manufacturing facility owned by Bharat Biotech International Ltd. revealed “deficiencies in good manufacturing practices.”
The WHO has not revealed the extent or nature of the deficiencies at Bharat Biotech’s facility; but given its recent instructions to U.N. agencies, the deficiency must have been significant from a public health perspective. Violations of current good manufacturing processes is nothing new to the Indian pharmaceutical industry. There is a sordid history of warning letters from the U.S. Food and Drug Administration documenting systematic compliance issues over the last decade. Foreign inspections all but ceased during the pandemic. Agencies such as the WHO rely on national regulatory agencies like the Central Drugs Standard Control Organisation (CDSCO), which regulates the pharmaceutical industry in India, to assess compliance before granting approval for commercial use of a drug.
This is not the first time that a foreign regulator has found problems with the manufacturing facility at Bharat Biotech that produces Covaxin. Exactly one year ago, the Agência Nacional de Vigilância Sanitária (ANVISA), Brazil’s drug regulator, pointed out serious lapses at Bharat Biotech’s manufacturing facility in India that makes this vaccine. ANVISA inspectors discovered issues with quality control at the facility that are meant to confirm that the live virus at the core of this vaccine has been inactivated.
At the time, the CDSCO remained a mute spectator to the affair and gave no assurances to the Indian public on measures it was taking to ensure that Bharat Biotech fixed these issues. It has followed the same path of silence since the WHO’s recent suspension of Covaxin’s procurement by the United Nations.
As I write this, not a single newspaper in India has been able to identify the exact nature of the deficiency the WHO raised, and few in India seem to be concerned about the implications of the WHO’s action, despite the fact that Covaxin is being administered to children in India.
India wants to be the ‘pharmacy of the world.’ But first, it must wean itself from China
India has embarked on an ambitious plan to cut dependence on China for key raw materials as it seeks to become self-sufficient in its quest to be the “pharmacy of the world.”
However, India’s $42 billion pharmaceutical sector is heavily dependent on China for key active pharmaceutical ingredients or API — chemicals that are responsible for the therapeutic effect of drugs.
Estimates put India’s dependence on China at as much as 90% for certain drugs.
an estimate by the Trade Promotion Council, a government supported organization, puts the figure of API dependence on China at about 85%. Another independent study carried out in 2021 points out that while India’s API imports from China are at nearly 70%, its dependence on China for “certain life-saving antibiotics” is around 90%. Some drugs that are highly dependent on Chinese APIs include penicillin, cephalosporins and azithromycin, the report said.
That may be starting to change.
Under a government scheme launched two years ago, 35 APIs began to be produced at 32 plants across India in March. This is expected to reduce dependence on China by up to 35% before the end of the decade, according to an estimate by ratings firm ICRA Limited, the Indian affiliate of Moody’s.
The production linked incentive scheme was first launched in mid-2020, when military tensions with China were at a high. The PLI program aims to incentivize companies across all sectors to boost domestic manufacturing by $520 billion by 2025.
For the pharma sector, the government has earmarked over $2 billion worth of incentives for both private Indian companies and foreign players to start producing 53 APIs that India relies heavily on China for.
Some of India’s biggest pharmaceutical companies are involved in the scheme. They include Sun Pharmaceutical Industries, Aurobindo Pharma, Dr. Reddy’s Laboratories, Lupin and Cipla.
A total of 34 products were approved in the first phase of the scheme — and distributed amongst 49 players, according to assistant vice president at ICRA Limited, Deepak Jotwani.
“The first phase will result in reduction in imports from China by about 25-35% by 2029,” Jotwani estimated.
India-made cough syrups may be tied to 66 deaths in Gambia: WHO | Business and Economy News | Al Jazeera
The WHO also issued a medical product alert asking regulators to remove Maiden Pharma goods from the market.
The deaths of dozens of children in The Gambia from kidney injuries may be linked to contaminated cough and cold syrups made by an Indian drug manufacturer, the World Health Organization said on Wednesday.
WHO Director-General Tedros Adhanom Ghebreyesus told reporters that the UN agency was conducting an investigation along with Indian regulators and the drugmaker, New Delhi-based Maiden Pharmaceuticals Ltd.
Maiden Pharma declined to comment on the alert, while calls and Reuters messages to the Drugs Controller General of India went unanswered. The Gambia and India’s health ministry also did not immediately respond to a request for comment.
The WHO also issued a medical product alert asking regulators to remove Maiden Pharma goods from the market.
The products may have been distributed elsewhere through informal markets, but had so far only been identified in The Gambia, the WHO said in its alert.
The alert covers four products – Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup.
Lab analysis confirmed “unacceptable” amounts of diethylene glycol and ethylene glycol, which can be toxic when consumed, the WHO said. The Gambia’s government said last month it has also been investigating the deaths, as a spike in cases of acute kidney injury among children under the age of five was detected in late July.
Medical officers in The Gambia raised the alarm in July, after several children began falling ill with kidney problems three to five days after taking a locally sold paracetamol syrup. By August, 28 had died, but health authorities said the toll would likely rise. Now 66 are dead, WHO said on Wednesday.
The deaths have shaken the tiny West African nation, which is already dealing with multiple health emergencies including measles and malaria.
Maiden Pharmaceuticals manufactures medicines at its facilities in India, which it then sells domestically, as well as exporting it to countries in Asia, Africa and Latin America, according to its website.
#India facing a #pandemic of #antibiotics-resistant superbugs. It is worst hit by what doctors call "antimicrobial resistance" - #antibiotic-resistant neonatal #infections alone are responsible for the deaths of nearly 60,000 newborns each year. #health https://www.bbc.com/news/world-asia-india-63059585
Things are so worrying that only 43% of the pneumonia infections caused by one pathogen in India could be treated with first line of antibiotics in 2021, down from 65% in 2016, the ICMR report says.
Saswati Sinha, a critical care specialist in AMRI Hospital in the eastern city of Kolkata, says things are so bad that "six out of 10" patients in her ICU have drug-resistant infections. "The situation is truly alarming. We have come to a stage where you are not left with too many options to treat some of these patients."
At the 1,000-bed not-for-profit Kasturba Hospital in the western Indian state of Maharashtra, doctors are grappling with a rash of antibiotic-resistant "superbug infections".
This happens when bacteria change over time and become resistant to drugs that are supposed to defeat them and cure the infections they cause.
Such resistance directly caused 1.27 million deaths worldwide in 2019, according to the Lancet medical journal. Antibiotics - which are considered to be the first line of defence against severe infections - did not work on most of these cases.
Millions are dying from drug-resistant infections
India is one of the countries worst hit by what doctors call "antimicrobial resistance" - antibiotic-resistant neonatal infections alone are responsible for the deaths of nearly 60,000 newborns each year. A new government report paints a startling picture of how things are getting worse.
Tests carried out at Kasturba Hospital to find out which antibiotic would be be most effective in tackling five main bacterial pathogens have found that a number of key drugs were barely effective.
These pathogens include E.coli (Escherichia coli), commonly found in the intestines of humans and animals after consumption of contaminated food; Klebsiella pneumoniae, which can infect the lungs to cause pneumonia, and the blood, cuts in the skin and the lining of the brain to cause meningitis; and the deadly Staphylococcus aureus, a food-borne bacteria that can be transmitted through air droplets or aerosols.
Doctors found that some of the main antibiotics were less than 15% effective in treating infections caused by these pathogens. Most concerning was the emergence of the multidrug-resistant pathogen called Acinetobacter baumannii, which attacks the lungs of patients on life support in critical care units.
Hidden pandemic of antibiotic-resistant infections
"As almost all our patients cannot afford the higher antibiotics, they run the real risk of dying when they develop ventilator-associated pneumonia in the ICU," Dr SP Kalantri, medical superintendent of the hospital, says.
A new report by Indian Council of Medical Research (ICMR) says that resistance to a powerful class of antibiotics called carbapenems - it defeats a number of pathogens - had risen by up to 10% in just one year alone. The report collects data on antibiotic resistance from up to 30 public and private hospitals every year.
"The reason why this is alarming is that it is a great drug to treat sepsis [a life-threatening condition] and sometimes used as a first line of treatment in hospitals for very sick patients in ICUs," says Dr Kamini Walia, a scientist at Indian Council of Medical Research (ICMR) and lead author of the study.
Necessary #Indian Drugs Prove Deadly For Dozens of Children. Deaths believed to be linked to contaminated #cough syrups in #Gambia have brought attention to loose #regulations in #India and a lack of testing capacity in poor importing nations. #health https://www.nytimes.com/2022/11/03/world/asia/india-gambia-cough-syrup.html?smid=tw-share
“What happened in Gambia is happening in other African countries without us even knowing,” said Michel Sidibé, the African Union special envoy for the African Medicines Agency, a new body aimed at harmonizing drug regulation across the continent.
“Most African countries don’t have testing capacities nor well-trained regulatory bodies,” Mr. Sidibé said. “The African market is very fragmented, but because of poor regulations, drugs move from one country to another.”
They had fevers, aches, runny noses, the normal stuff of childhood. The kind of illnesses for which a doctor would prescribe cough syrup.
But the children’s condition only worsened. They developed persistent diarrhea, then could no longer urinate, as their kidneys failed. The very medicines that were supposed to make them better, simple cough syrups imported from India, were instead killing them, because they turned out to be poison.
In all, 70 children in the tiny West African nation of Gambia are suspected to have died in recent months from contaminated Indian-made cough syrups. Among them was 2-year-old Muhammad Lamin Kijera, who died on Aug. 4.
“He was lively and likable — he was everybody’s friend,” said his father, Alieu Kijera, who works as a nurse at an eye clinic in Banjul, the Gambian capital. “How can they allow something like this into the country, destroying lives?”
India has taken to calling itself “the world’s pharmacy” as its drug industry has expanded rapidly, providing a lifeline to the developing world by selling medicines, many of them generics, for an array of illnesses like malaria and AIDS at prices lower than those of American or European drugs.
But the deaths in Gambia have raised alarm over what one expert called a “dangerous cocktail”: on one side, a $50 billion Indian pharmaceutical industry whose regulation has remained loose and chaotic despite repeated calamities, and on the other, poor nations with little or no way to test the quality of the medicines they import.
India’s drug industry, experts say, is rife with data fraud, inadequate testing and substandard manufacturing practices. While people around the world take Indian medicines every day without incident, the regulatory weaknesses give the country’s drug makers openings to cut corners and increase profits, experts say.
That has created a hazardous reality far more widespread than the occasional tragic cases of mass poisonings, and could shake faith in Indian medicines in the places that need them most.
India is the world’s third-largest drug manufacturer by volume, producing 60 percent of global vaccines and 20 percent of generic medicines. In a sign of the world’s reliance on Indian drugs, the country’s pharmaceutical exports increased nearly 20 percent during the first year of the pandemic, reaching $24 billion, despite lockdowns that disrupted global supply chains.
As a stamp of approval for the quality of Indian medicines, officials point out that more than half of the drugs manufactured in India go to highly regulated markets — “every third pill in the U.S. and every fourth pill in Europe is sold from India,” according to the Indian Pharmaceutical Alliance.
As the Covid-19 pandemic spread across the world two years ago, one of India’s leading biotech companies was racing to develop a vaccine with crucial backing from the Indian government. The shot engineered by Bharat Biotech was, in part, an important effort to create a home-grown product that could bolster the fortunes of the Indian pharmaceutical industry.
However, a STAT review of documents detailing the steps taken toward government approval found that regulators endorsed the vaccine, called Covaxin, despite discrepancies in the number of clinical trial participants. Moreover, questionable changes were made to the trial protocols — which are established procedures for testing a vaccine or medicine — to expedite the approval process.
For instance, the number of people enrolled in the Phase 1 portion of the trial differed from what was later published in a medical journal. There were also important changes made to the protocol for Phase 2 testing, when immunogenicity data from the previous Phase 1 stage were not yet available.
In addition, the protocol for Phase 3 was approved while Phase 2 was still underway and the final vaccine candidate was selected without Phase 2 data, according to protocol documents and minutes of meetings held by an expert committee that reported to India’s Central Drugs Standard Control Organization (CDSCO), the national regulator responsible for approving medicines. This was the agency that authorized the vaccine for emergency use in January 2021, two months before Phase 3 results were known.
More controversy erupted last spring. Brazilian authorities raised concerns about Bharat Biotech manufacturing. Then, the WHO, which listed the vaccine for emergency use in November 2021, suspended supplies after an inspection of the facilities found unspecified problems. The decision meant United Nations procurement agencies, such as UNICEF, would no longer be able to supply the shot to other countries. A WHO spokesperson declined to offer an update on the findings.
For now, it remains unclear whether the newly disclosed issues surrounding the clinical trial will trigger still more questions about the willingness of the Indian government to boost its oversight. The CDSCO and the Drugs Controller General of India, which oversees the CDSCO, did not respond to emails seeking comment about the changes made to the Covaxin trial protocols and subsequent government approval.
In reviewing the documents, there was a clear discrepancy in the number of enrollees. In reporting the Phase 1/2 data, the protocol stated 402 participants were given the first dose and 394 got the second dose. But results published in Lancet Infectious Diseases in January 2021 stated 375 people were given a first dose and 368 received a second dose. (See Figure 1 on page 640.)
#India still uses #asbestos. Poor #Indians use it for roofing. WHO says all asbestos types cause “lung cancer, mesothelioma, cancer of the larynx and ovary, and asbestosis [fibrosis of the lungs]”. Exposure, handling or inhaling it results in death.
Asbestos – a cheap, heat-resistant mineral – was once used widely in building materials all around the world. Today, it is banned in 70 countries which have deemed that this construction material is a “silent killer” since its fibres are carcinogenic.
While there are six types of asbestos, chrysotile – white asbestos – is the most common form, used especially in roofing houses.
According to the World Health Organization, all types of asbestos cause “lung cancer, mesothelioma, cancer of the larynx and ovary, and asbestosis [fibrosis of the lungs]”.
Exposure to the fibres and handling or inhaling them could also result in death.
Yet some countries like India continue trading it.
In 2011, India banned asbestos mining and asbestos waste used in ships. But it continues to trade in raw asbestos and asbestos-based products, commonly found in the roofs of houses, especially in poorer regions of the country.
According to a November 2021 report by the Indian government, between 2019 and 2020, India imported 361,164 tonnes of asbestos, a 1 percent decrease compared with 364,105 tonnes in the previous year.
The report noted that almost the entire import was chrysotile asbestos, with 85 percent of these fibres coming from Russia. About 3 percent also came from Brazil, Kazakhstan and Hungary each, and 2 percent came from Poland and South Africa respectively.
Aaron Cosbey, a development economist and head of Small World Sustainability, a consultancy, told Al Jazeera that trade goes on because commercial interests have been prioritised over human welfare.
“India’s biggest source of chrysotile asbestos – Russia – has not banned it nationally. So there is no hypocrisy; it is just bad policy, given that the WHO and 70 states worldwide have agreed that there are no safe uses for the substance,” he said.
India also exports asbestos, but its sales have decreased substantially to 1,001 tonnes between 2019 and 2020, compared with 1,112 tonnes in the previous year.
The Indian government’s November 2021 report noted that most of the exports went to Bangladesh, and 7 percent to Sri Lanka.
Gopal Krishna, an environmental lawyer and co-founder of the Ban Asbestos Network of India, said despite countries like Brazil ruling that asbestos use was unconstitutional – and Hungary, Poland and South Africa banning asbestos – India continues with its import and export.
“The trade continues because nobody in India has time to deal with health complaints when money is involved and there is a lewd relationship between the Indian government and the asbestos manufacturers in the country,” he told Al Jazeera.
“A 2012 study (PDF) was conducted by the National Institute of Occupational Health in Ahmedabad, India, surveying 1,248 workers exposed to the substance. Noting that the fibres affected only three workers, the study concluded that asbestos and its derivatives are not harmful to human health. But this study by a government body was co-sponsored by the Asbestos Cement Products Manufacturers’ Association, which lobbies for the industry, making it a conflict of interest,” he added.
Krishna said the study contradicts the UN Rotterdam Convention, which was adopted in 2004 and reviews the harmful effects of a wide range of chemicals and pesticides.
Post a Comment